We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
201
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$85K 0.01%
+111
New +$599
AGEN
202
CALL
Agenus
AGEN
$275M
$79K 0.01%
15
-3
-17% -$155
CYTR
203
CALL
DELISTED
CytRx Corp
CYTR
$78K 0.01%
21
– –
SQNM
204
CALL
DELISTED
SEQUENOM INC NEW
SQNM
$69K ﹤0.01%
293
– –
OREX
205
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$68K ﹤0.01%
12
-44
-79% -$2.47K
ASMB icon
206
PUT
Assembly Biosciences
ASMB
$507M
$61K ﹤0.01%
+3
New +$546
RNA
207
PUT
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$56K ﹤0.01%
+120
New +$547
SQNM
208
DELISTED
SEQUENOM INC NEW
SQNM
$48K ﹤0.01%
20,500
+5,100
+33% +$12.1K
SQNM
209
PUT
DELISTED
SEQUENOM INC NEW
SQNM
$48K ﹤0.01%
205
– –
NWBO
210
CALL
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$44K ﹤0.01%
+118
New +$457
AMRN
211
PUT
Amarin Corp
AMRN
$293M
$38K ﹤0.01%
10
-144
-94% -$7.46K
SEEL
212
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
ANIP icon
213
ANI Pharmaceuticals
ANIP
$1.84B
$24K ﹤0.01%
+1,219
New +$15.8K
WINT
214
CALL
DELISTED
Windtree Therapeutics Inc
WINT
$23K ﹤0.01%
+7
New +$219
IMUC
215
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$23K ﹤0.01%
+625
New +$59.2K
NKTR icon
216
Nektar Therapeutics
NKTR
$2.39B
$6K ﹤0.01%
+33
New +$5.32K
AGEN
217
Agenus
AGEN
$275M
– –
-89,859
Closed -$4.63M
ARAY icon
218
CALL
Accuray
ARAY
$29M
– –
-254
Closed -$188K
ARAY icon
219
Accuray
ARAY
$29M
– –
-100,000
Closed -$739K
ARAY icon
220
PUT
Accuray
ARAY
$29M
– –
-1,400
Closed -$1.03M
AZN icon
221
CALL
AstraZeneca
AZN
$267B
– –
-241
Closed -$1.25M
AZN icon
222
AstraZeneca
AZN
$267B
– –
-26,585
Closed -$1.38M
AZN icon
223
PUT
AstraZeneca
AZN
$267B
– –
-2,060
Closed -$10.7M
BB icon
224
PUT
BlackBerry
BB
$4.74B
– –
-6,296
Closed -$5M
BMRN icon
225
CALL
BioMarin Pharmaceuticals
BMRN
$12B
– –
-417
Closed -$3.01M
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.